Tableaux LLC Takes $7.99 Million Position in IDEXX Laboratories, Inc. $IDXX

Tableaux LLC bought a new position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 14,901 shares of the company’s stock, valued at approximately $7,992,000. IDEXX Laboratories accounts for about 0.6% of Tableaux LLC’s investment portfolio, making the stock its 16th biggest position.

Other hedge funds have also bought and sold shares of the company. Mutual of America Capital Management LLC raised its position in IDEXX Laboratories by 79.6% in the 1st quarter. Mutual of America Capital Management LLC now owns 19,430 shares of the company’s stock valued at $8,160,000 after buying an additional 8,609 shares during the last quarter. Private Advisor Group LLC grew its stake in shares of IDEXX Laboratories by 16.5% in the 1st quarter. Private Advisor Group LLC now owns 2,088 shares of the company’s stock worth $877,000 after acquiring an additional 295 shares in the last quarter. Kestra Private Wealth Services LLC grew its stake in shares of IDEXX Laboratories by 4.7% in the 1st quarter. Kestra Private Wealth Services LLC now owns 2,014 shares of the company’s stock worth $846,000 after acquiring an additional 91 shares in the last quarter. Choreo LLC raised its holdings in shares of IDEXX Laboratories by 4.3% in the first quarter. Choreo LLC now owns 1,544 shares of the company’s stock valued at $648,000 after purchasing an additional 64 shares during the last quarter. Finally, Wedbush Securities Inc. lifted its position in shares of IDEXX Laboratories by 1.3% during the first quarter. Wedbush Securities Inc. now owns 2,145 shares of the company’s stock valued at $901,000 after purchasing an additional 28 shares in the last quarter. Institutional investors and hedge funds own 87.84% of the company’s stock.

Insiders Place Their Bets

In other news, EVP Nimrata Hunt sold 9,425 shares of the stock in a transaction on Friday, November 7th. The stock was sold at an average price of $703.34, for a total value of $6,628,979.50. Following the sale, the executive vice president directly owned 21,149 shares of the company’s stock, valued at approximately $14,874,937.66. This represents a 30.83% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Company insiders own 0.98% of the company’s stock.

IDEXX Laboratories Price Performance

IDXX opened at $725.91 on Friday. IDEXX Laboratories, Inc. has a 12-month low of $356.14 and a 12-month high of $735.59. The company has a current ratio of 1.11, a quick ratio of 0.79 and a debt-to-equity ratio of 0.31. The stock has a 50-day moving average price of $656.12 and a 200-day moving average price of $595.80. The stock has a market capitalization of $57.96 billion, a P/E ratio of 60.44, a PEG ratio of 4.06 and a beta of 1.62.

IDEXX Laboratories (NASDAQ:IDXX) last posted its quarterly earnings results on Monday, November 3rd. The company reported $3.22 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.14 by $0.08. The business had revenue of $1.11 billion for the quarter, compared to analyst estimates of $1.07 billion. IDEXX Laboratories had a return on equity of 64.42% and a net margin of 24.41%.IDEXX Laboratories’s revenue for the quarter was up 13.3% compared to the same quarter last year. During the same period last year, the company earned $2.80 EPS. IDEXX Laboratories has set its FY 2025 guidance at 12.810-13.010 EPS. Equities analysts predict that IDEXX Laboratories, Inc. will post 11.93 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts recently commented on IDXX shares. Wall Street Zen raised IDEXX Laboratories from a “buy” rating to a “strong-buy” rating in a research report on Sunday, November 16th. Morgan Stanley raised their target price on IDEXX Laboratories from $765.00 to $805.00 and gave the company an “overweight” rating in a research report on Tuesday, November 4th. Stifel Nicolaus set a $775.00 price target on shares of IDEXX Laboratories in a report on Monday, November 3rd. Weiss Ratings restated a “hold (c+)” rating on shares of IDEXX Laboratories in a research report on Wednesday. Finally, Leerink Partners set a $785.00 price objective on shares of IDEXX Laboratories in a research report on Monday, November 3rd. One investment analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and four have assigned a Hold rating to the stock. Based on data from MarketBeat.com, IDEXX Laboratories presently has a consensus rating of “Moderate Buy” and a consensus price target of $730.50.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.